Beigene Ltd
ONC267.125USD
+0.325+0.12%
終値 06/25, 16:00（ET）15分遅れの株価
26.47B時価総額
損失額直近12ヶ月PER
詳細情報 BeOne Medicines AG 企業名
BeOne Medicines Ltd., formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
企業情報
企業コードONC
会社名BeOne Medicines AG
上場日- -
設立日2025
最高経営責任者「CEO」Mr. John Victor Oyler
従業員数11000
証券種類Ordinary Share
決算期末- -
本社所在地c/o BeOne Medicines I GmbH
都市BASEL
証券取引所The Toronto Stock Exchange
国Switzerland
郵便番号4051
電話番号41616851900
ウェブサイト
企業コードONC
上場日- -
設立日2025
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
12.26K
-25.10%
Mr. Lai Wang
Mr. Lai Wang
Global Head of R&D
Global Head of R&D
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Giancarlo Benelli
Mr. Giancarlo Benelli
Senior Vice President, Head of Europe
Senior Vice President, Head of Europe
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
12.26K
-25.10%
Mr. Lai Wang
Mr. Lai Wang
Global Head of R&D
Global Head of R&D
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Giancarlo Benelli
Mr. Giancarlo Benelli
Senior Vice President, Head of Europe
Senior Vice President, Head of Europe
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
収益内訳
通貨: USD更新時刻: Sun, Apr 6
通貨: USD更新時刻: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
事業別USD
会社名
収益
比率
Product
3.72B
97.62%
BRUKINSA
2.64B
69.40%
Tislelizumab
620.84M
16.29%
XGEVA
224.40M
5.89%
BLINCYTO
74.33M
1.95%
Other
-3.47B
-91.15%
地域別USD
会社名
収益
比率
United States
1.96B
51.37%
China
1.41B
37.04%
Europe
362.63M
9.52%
ROW
78.81M
2.07%
事業別
地域別
事業別USD
会社名
収益
比率
Product
3.72B
97.62%
BRUKINSA
2.64B
69.40%
Tislelizumab
620.84M
16.29%
XGEVA
224.40M
5.89%
BLINCYTO
74.33M
1.95%
Other
-3.47B
-91.15%
株主
更新時刻: Tue, Jun 24
更新時刻: Tue, Jun 24
株主統計
種類
株主統計
株主統計
比率
Amgen Inc
17.28%
Baker Bros. Advisors LP
8.03%
Capital International Investors
4.64%
PRIMECAP Management Company
4.61%
Baillie Gifford & Co.
3.31%
Other
62.12%
株主統計
株主統計
比率
Amgen Inc
17.28%
Baker Bros. Advisors LP
8.03%
Capital International Investors
4.64%
PRIMECAP Management Company
4.61%
Baillie Gifford & Co.
3.31%
Other
62.12%
種類
株主統計
比率
Investment Advisor
21.77%
Corporation
17.31%
Hedge Fund
10.90%
Investment Advisor/Hedge Fund
4.86%
Sovereign Wealth Fund
1.32%
Research Firm
0.89%
Pension Fund
0.21%
Bank and Trust
0.11%
Family Office
0.02%
Other
42.61%
機関投資家保有株
更新時刻: Mon, Jan 20
更新時刻: Mon, Jan 20
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q1
559
66.79M
67.51%
+1.06M
2024Q4
575
70.01M
71.38%
+1.65M
2024Q3
603
67.03M
68.90%
-2.04M
2024Q2
601
66.99M
69.35%
-2.19M
2024Q1
621
66.56M
67.86%
-955.35K
2023Q4
626
65.12M
66.49%
-3.71M
2023Q3
632
67.27M
67.88%
-2.05M
2023Q2
655
66.79M
67.58%
-3.13M
2023Q1
655
67.68M
71.16%
-4.10M
2022Q4
657
69.40M
73.25%
-5.85M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Amgen Inc
18.94M
19.16%
--
--
Feb 20, 2025
Baker Bros. Advisors LP
8.80M
8.9%
-732.83K
-7.69%
Feb 28, 2025
Capital International Investors
6.11M
6.18%
-317.72K
-4.94%
Dec 31, 2024
PRIMECAP Management Company
5.10M
5.16%
+124.61K
+2.51%
Dec 31, 2024
Baillie Gifford & Co.
3.67M
3.71%
-34.56K
-0.93%
Dec 31, 2024
Fidelity Management & Research Company LLC
1.78M
1.8%
+174.46K
+10.84%
Dec 31, 2024
T. Rowe Price Associates, Inc.
1.49M
1.51%
+109.68K
+7.93%
Dec 31, 2024
T. Rowe Price International Ltd
1.44M
1.46%
+127.40K
+9.67%
Dec 31, 2024
HHLR Advisors, Ltd.
1.32M
1.34%
-2.48M
-65.19%
Mar 03, 2025
Temasek Holdings Pte. Ltd.
1.53M
1.54%
-863.25K
-36.14%
Dec 31, 2024
詳細を見る
関連ETF
更新時刻: Mon, Jun 2
更新時刻: Mon, Jun 2
銘柄名
比率
First Trust NYSE Arca Biotechnology Index Fund
3.51%
Innovator IBD 50 Fund ETF
3.07%
Tema Oncology ETF
2.94%
Virtus LifeSci Biotech Products ETF
2.51%
VanEck Biotech ETF
2.23%
Global X Aging Population ETF
2.05%
iShares Health Innovation Active ETF
1.51%
iShares Biotechnology ETF
1.42%
Invesco Nasdaq Biotechnology ETF
1.17%
ProShares Ultra Nasdaq Biotechnology
1.17%
詳細を見る
First Trust NYSE Arca Biotechnology Index Fund
比率3.51%
Innovator IBD 50 Fund ETF
比率3.07%
Tema Oncology ETF
比率2.94%
Virtus LifeSci Biotech Products ETF
比率2.51%
VanEck Biotech ETF
比率2.23%
Global X Aging Population ETF
比率2.05%
iShares Health Innovation Active ETF
比率1.51%
iShares Biotechnology ETF
比率1.42%
Invesco Nasdaq Biotechnology ETF
比率1.17%
ProShares Ultra Nasdaq Biotechnology
比率1.17%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
